(Q35597328)

English

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy

scientific article published on October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy (English)

1 reference

Europe PubMed Central

9 August 2017

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

William G Wierda

3

object named as

William Wierda

1 reference

Europe PubMed Central

9 August 2017

6

object named as

Susan O'Brien

1 reference

Europe PubMed Central

9 August 2017

Michael J. Keating

8

object named as

Michael J Keating

1 reference

Europe PubMed Central

9 August 2017

7

object named as

Susan Lerner

1 reference

Europe PubMed Central

9 August 2017

Lynne V Abruzzo

4

object named as

Lynne Abruzzo

1 reference

Europe PubMed Central

9 August 2017

Constantine S. Tam

9

object named as

Constantine Tam

1 reference

Europe PubMed Central

9 August 2017

1

object named as

Ellen J Schlette

1 reference

Europe PubMed Central

9 August 2017

Joan H Admirand

2

object named as

Joan Admirand

1 reference

Europe PubMed Central

9 August 2017

Katherine I Lin

5

object named as

Katherine I Lin

1 reference

Europe PubMed Central

9 August 2017

publication date

1 October 2009

1 reference

Europe PubMed Central

9 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

9 August 2017

50

1 reference

Europe PubMed Central

9 August 2017

1597-1605

1 reference

Europe PubMed Central

9 August 2017

10

1 reference

Europe PubMed Central

9 August 2017

describes a project that uses

immunohistochemistry

1 reference

based on heuristic

inferred from title

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Primary carcinoma of the fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Cytogenetics in chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Genes and chromosomes in chronic B-cell leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Genetic abnormalities in chronic lymphocytic leukemia and their clinical and prognostic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Prognostic significance of karyotypic abnormalities in B cell chronic lymphocytic leukemia: an update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

27 July 2018

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Dissecting p53-dependent apoptosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4428664

26 September 2018

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

The importance of p53 location: nuclear or cytoplasmic zip code?

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

A dual role of p53 in the control of autophagy

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190903165241

21 January 2018

A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosomal abnormalities in B-CLL

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TP53 abnormalities and genetic instability in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19863337

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/10428190903165241

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35597328&oldid=1878981187"